Published in Arch Ophthalmol on August 01, 1996
Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol (1997) 2.73
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest (1996) 1.76
Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol (2002) 1.59
Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 1.59
Vascular endothelial growth factor and ocular neovascularization. Am J Pathol (1997) 1.56
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol (2001) 1.53
Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol (2008) 1.45
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 1.39
Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34
Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 1.34
Neovascular glaucoma. Prog Retin Eye Res (2007) 1.31
Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol (2013) 1.30
Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol (1997) 1.29
Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest (2004) 1.16
High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics (2010) 1.16
Retinopathy of prematurity: recent advances in our understanding. Br J Ophthalmol (2002) 1.15
Retinopathy of prematurity: recent advances in our understanding. Arch Dis Child Fetal Neonatal Ed (2002) 1.12
Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm (2010) 1.11
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol (2009) 0.99
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol (2003) 0.99
Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res (2015) 0.99
Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients. PLoS One (2014) 0.94
Alternative therapies in exudative age related macular degeneration. Br J Ophthalmol (1998) 0.93
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol (2009) 0.92
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. J Ophthalmol (2011) 0.90
Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging (2006) 0.89
Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents. J Biol Chem (2014) 0.85
Surgical results of pars plana vitrectomy combined with pars plana lensectomy with anterior capsule preservation, endophotocoagulation, and silicon oil tamponade for neovascular glaucoma. Clin Ophthalmol (2011) 0.85
Current status of anti-vascular endothelial growth factor therapy in Europe. Jpn J Ophthalmol (2008) 0.85
Targeting Neovascularization in Ischemic Retinopathy: Recent Advances. Expert Rev Ophthalmol (2013) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol (2007) 0.84
The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model. Clinics (Sao Paulo) (2011) 0.81
Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci (2016) 0.81
The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol (2013) 0.80
Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. J Ophthalmic Vis Res (2009) 0.80
[Antiangiogenic treatment for neovascular glaucoma and after filtering surgery]. Ophthalmologe (2009) 0.79
Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization. Sci Rep (2017) 0.78
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture. Transl Vis Sci Technol (2016) 0.78
Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization. J Ophthalmol (2013) 0.77
Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF. Int J Mol Sci (2014) 0.77
Alternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic Inflammation. Rev Diabet Stud (2015) 0.77
Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma. PLoS One (2015) 0.77
Impact of Intravitreal Injection of Bevacizumab (Avastin) on Rabbit's Choroid and Retina. Middle East Afr J Ophthalmol (2008) 0.75
Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma. Trans Am Ophthalmol Soc (2016) 0.75
Temporal and spatial changes in VEGF, αA- and αB-crystallin expression in a mouse model of oxygen-induced retinopathy. Int J Clin Exp Med (2015) 0.75
Alterations of plasma nitric oxide, vascular endothelial growth factor, and soluble form of its receptor (sFlt-1) after resistance exercise: An experimental study. Adv Biomed Res (2014) 0.75
Neovascular glaucoma: a review. Int J Retina Vitreous (2016) 0.75
Effects of ranibizumab on TGF-β1 and TGF-β2 production by human Tenon's fibroblasts: An in vitro study. Mol Vis (2015) 0.75
A novel in vivo model of puncture-induced iris neovascularization. PLoS One (2017) 0.75
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol (1999) 8.96
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol (1999) 8.92
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A (1995) 5.92
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 5.76
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA (1994) 5.43
Current treatment of metastatic choroidal tumors. Oncology (Williston Park) (1989) 5.15
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res (1996) 4.75
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A (1999) 4.05
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol (2001) 3.26
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci (2001) 3.08
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem (1997) 2.95
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Proc Natl Acad Sci U S A (1983) 2.92
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Epidemiologic aspects of uveal melanoma. Surv Ophthalmol (1988) 2.85
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Interferon-associated retinopathy. Arch Ophthalmol (1993) 2.73
Infraslow oscillations modulate excitability and interictal epileptic activity in the human cortex during sleep. Proc Natl Acad Sci U S A (2004) 2.69
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology (1998) 2.62
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem (1996) 2.58
Ocular blood flow velocity in age-related macular degeneration. Ophthalmology (1995) 2.53
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
Response of the Peritoneal Tissue to Dusts Introduced as Foreign Bodies. Am J Public Health Nations Health (1935) 2.37
Adverse reactions due to indocyanine green. Ophthalmology (1994) 2.30
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci (2001) 2.24
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest (1992) 2.19
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol (1992) 2.14
Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol (2002) 2.12
VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest (1999) 2.08
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation (1995) 2.07
Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci (2000) 2.05
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology (2006) 2.04
Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol (2000) 2.03
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol (2008) 2.03
Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate (1998) 2.02
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res (2000) 2.02
Angiogenesis and bone growth. Trends Cardiovasc Med (2000) 1.98
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation (1995) 1.92
Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol (1999) 1.90
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90
Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem (1998) 1.89
VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci (1999) 1.89
Retinal manifestations of neurofibromatosis. Diagnosis and management. Arch Ophthalmol (1991) 1.88
Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res (1996) 1.86
Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev (1997) 1.86
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest (1998) 1.85
Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein. Nucleic Acids Res (1999) 1.85
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors (1992) 1.84
Evaluation of prior primary malignancy as a determinant of uveal melanoma. A case-control study. Ophthalmology (1989) 1.82
Neuronal regulation of glutamate transporter subtype expression in astrocytes. J Neurosci (1997) 1.81
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology (2006) 1.80
Ocular neovascularization: an epidemiologic review. Surv Ophthalmol (1999) 1.79
Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med (1995) 1.78
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci (1998) 1.77
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest (1996) 1.76
Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr (1997) 1.75
High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. J Am Coll Cardiol (2001) 1.75
Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem (1996) 1.73
Transient global amnesia: clinical characteristics and prognosis. Neurology (1987) 1.72
Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest (2005) 1.68
Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. Proc Natl Acad Sci U S A (1997) 1.66
Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab (1996) 1.64
Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol (2001) 1.64
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol (2001) 1.64
Clinical course of macular holes: the Eye Disease Case-Control Study. Arch Ophthalmol (1999) 1.64